… vitamin K antagonist warfarin was the mainstay of anticoagulation before the introduction of
DOACs (apixaban, … clinical practice through a multinational population-based cohort study. …

… (double versus triple therapy and apixaban versus VKA), for … trials, we prioritized comparative
data of apixaban+SAPT and … versus triple therapy regimens were available (ie, for patient …

… with the historical gold standard vitamin K antagonists (VKAs) in … naive patients with
non-valvular AF in a large German claims … and that certain patients seen in routine practice will …

… Because of their ease of use in routine clinical practice and their excellent efficacy and …
apixaban is a cost-saving alternative to warfarin therapy for the prevention of stroke in patients …

… initiators; apixaban and warfarin patients were also more likely … of anticoagulants in routine
clinical practice. Other strengths … cohorts for comparative effectiveness assessment across the …

… safety or efficacy were observed between apixaban 2.5 mg BID and vitamin K antagonists in
patients with atrial fibrillation … in Germany, randomized comparison of a standardized NOAC …

… comparison of persistence and adherence between NOACs an essential aspect of the
overall relative comparative effectiveness … with apixaban in Denmark, Norway, and Germany, …

… Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of ischemic stroke
five-fold [1]. While vitamin K antagonists … inhibitors rivaroxaban, apixaban, and edoxaban, …

… Albeit this would mimic (future) clinical practice, it could have impacted our results. … comparing
apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation…

… After the launch of DOACs, several comparative effectiveness studies have been conducted
… of how routine oral anticoagulation is delivered in clinical practice and supplements data …